ALLO-ASC-SHEET / Anterogen - LARVOL DELTA

Clinical Study of ALLO-ASC-SHEET in Subjects with Diabetic Foot Ulcers (clinicaltrials.gov) - P2 | N=66 | Completed | Sponsor: Anterogen Co., Ltd. | Active, not recruiting ➔ Completed

Trial completion

Study to Evaluate Safety and Efficacy of ALLO-ASC-SHEET in Subjects With Dystrophic Epidermolysis Bullosa (clinicaltrials.gov) - P2 | N=6 | Recruiting | Sponsor: Anterogen Co., Ltd. | Trial completion date: Feb 2025 ➔ Apr 2026 | Trial primary completion date: Nov 2024 ➔ Oct 2025

Trial completion date • Trial primary completion date • COL7A1

Exploring the Financial Burden Associated with the Management of Dystrophic Epidermolysis Bullosa (DEB): A Systematic Literature Review (SLR) with Database Review of Future Disease-Modifying Therapies (DMTs) (ISPOR 2024) - "Nine clinical trials research 7 potential DMTs: advanced/gene therapies (EB-101, B-VEC, ALLO-ASC-SHEET, FCX-007), protein-replacement therapies (PTR-01, PTR-01-002), and a proteinase inhibitor (Polyphenon E). Previously, as there were no DMT options for patients with DEB treatment was symptomatic only. Future innovative DMTs should aim to prevent skin wounds, thereby decreasing the need for hospitalization and outpatient visits."

Review • Dermatology • Gene Therapies